)
Aurobindo Pharma is trading higher by 2% at Rs 727 in otherwise weak market after reporting a robust consolidated net profit of Rs 415 crore for the quarter ended June 30, 2014 (Q1), on back of strong operational performance. The drug maker had profit of Rs 19 crore in the same quarter last year.
The consolidated net revenues from operations grew by 70% at Rs 2,895 crore during the quarter under review as against Rs 1,700 crore in the previous year.
The EBITDA or operating profit margin during the quarter Y-o-Y basis has improved by 460bps to 22.6% on account of improvement business mix resulting in decrease in materials consumption, staff cost to net operating income by 4.5%, 0.4% respectively, Aurobindo Pharma said in a statement.
Meanwhile, the company hopes to seek approvals for nine more injectables from US FDA.
The board has also approved interim dividend of 150% i.e. Rs 1.50 per share of Re 1 each on the equity share capital of the company for the year 2014-15.
The stock opened at Rs 725 and touched a high of Rs 734 on NSE. A combined 1.64 million shares changed hands on the counter so far on NSE and BSE.
The consolidated net revenues from operations grew by 70% at Rs 2,895 crore during the quarter under review as against Rs 1,700 crore in the previous year.
The EBITDA or operating profit margin during the quarter Y-o-Y basis has improved by 460bps to 22.6% on account of improvement business mix resulting in decrease in materials consumption, staff cost to net operating income by 4.5%, 0.4% respectively, Aurobindo Pharma said in a statement.
Meanwhile, the company hopes to seek approvals for nine more injectables from US FDA.
The board has also approved interim dividend of 150% i.e. Rs 1.50 per share of Re 1 each on the equity share capital of the company for the year 2014-15.
The stock opened at Rs 725 and touched a high of Rs 734 on NSE. A combined 1.64 million shares changed hands on the counter so far on NSE and BSE.
